Hairy cell leukemia and pregnancy


Cite item

Full Text

Abstract

The paper presents experience in following up and treating hairy cell leukemia (HCL) during pregnancy. The combination of HCL and pregnancy was observed in 5 patients. The patients’ median age was 35 years (range, 28—42 years). The diagnosis of HCL was based on a conventional examination protocol: clinical blood analysis with the morphological assessment of lymphocytes, a myelogram and trepanobiopsy, immunophenotypic analysis of lymphocytes or bone marrow (in all the patients), cytochemical determination of tartrate-resistant acid phosphatase in 3 patients, and identification of BRAFV600E mutation in 3 patients. Three pregnant women were treated for HCL in the postpartum period. In one patient with HCL, pregnancy was seen in remission after treatment with cladribine. In one patient with HCL detected at 11 weeks’ gestation, interferon-α therapy during the second trimester of pregnancy was performed for increased cytopenia, which was followed by cladribine therapy after delivery. Pregnancy and delivery were uncomplicated in all the patients; 3 patients had vaginal delivery and 2 patients underwent cesarean section. All infants were healthy, with no developmental abnormalities during a follow-up period of 6—140 months (median 30 months). All the patients with HCL are currently in remission: 4 patients in first remission at a follow-up of 10 to 48 months (median 15 months) and one patient in second remission at a follow-up of 88 months. Possible observational tactics is possible when HCL is detected during pregnancy. Treatment of HCL during pregnancy is necessary in cases of deep or progressive cytopenia and/or splenomegaly. The use of interferon-α or splenectomy is preferable.

About the authors

L S Al-radi

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

T N Moiseeva

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

S Yu Smirnova

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

R G Shmakov

ФГБУ «Научный центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова» Минздрава России

Москва, Россия

References

  1. Chadha P, Rademaker AW, Mendiratta P, Kim B, Evanchuk DM, Hakimian D, Peterson LC, Tallman MS. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005; 106(1):241-246. https://doi.org/10.1182/blood-2005-01-0173
  2. Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZ, Johnson SA, O’Connor NT, Haynes A, Osuji N, Forconi F, Lauria F, Catovsky D. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145(6):733-740. https://doi.org/10.1111/j.1365-2141.2009.07668.x
  3. Maloisel F, Benboubker L, Gardembas M, Coiffier B, Divine M, Sebban C, Blanc M, Abgrall JF, Lederlin P, Harousseau JL, Blaise AM, Grosbois B, Morice P, Ghandour C, Castaigne S. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia. 2003;17(1):45-51.
  4. Zinzani PL, Tani M, Marchi E, Stefoni V, Alinari L, Musuraca G, Gabriele A, Pileri S, Baccarani M. Long-term follow-up of frontline treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica. 2004;89(3):309-313.
  5. Else M, Ruchlemer R, Osuji N, Del Giudice I, Matutes E, Woodman A, Wotherspoon A, Swansbury J, Dearden C, Catovsky D. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12,5 years. Cancer. 2005,104:2442-2448. https://doi.org/10.1002/cncr.21447
  6. Chadha P, Rademaker AW, Mendiratta P, Kim B, Evanchuk DM, Hakimian D, Peterson LC, Tallman MS. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005; 106(1):241-246. https://doi.org/10.1182/blood-2005-01-0173
  7. Dearden CE, Else M, Catovsky D. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma. 2011;52(Suppl.2):21-24. https://doi.org/10.3109/10428194.2011.565093
  8. Getta BM, Woo KM, Devlin S, Park JH, Abdel-Wahab O, Saven A, Rai K,Tallman MS. Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia. British Journal of Haematology. 2016;175(3):402-409. https://doi.org/10.1111/bjh.14207
  9. Rosenberg JD, Burian C, Waalen J, Saven A. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood. 2014; 123(2):177-183. https://doi.org/10.1182/blood-2013-06-508754
  10. Аль-Ради Л.С., Самойлова Р.С., Тихонова Л.Ю, Дягилева О.А., Наумова И.В., Капланская И.Б., Варламова Е.Ю. Волосатоклеточный лейкоз у больных молодого возраста. Терапевтическийархив. 2008;12:53-58.
  11. Williams JK. Hairy cell leukemia in pregnancy: a case report. Am J Obstet Gynecol. 1987;156:210-211.
  12. Kopeć I, Debski R, Samsel M, Winter W, Maryniak R, Prochorec M, Podstawka U, Maj S, Banaczek Z, Warzocha K. Hairy cell leukemia in pregnancy. Ginekol Pol. 2005;76(11):898-901.
  13. Baer MR, Ozer H, Foon KA. Interferon-alpha therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia. Br J Haematol. 1992;81(2):167-169. https://doi.org/10.1111/j.1365-2141.1992.tb08202.x
  14. Stiles GM, Stanco LM, Saven A, Hoffmann KD. Splenectomy for hairy cell leukemia in pregnancy. J Perinatol. 1998;18:200-201.
  15. Bustamante A, Rodríguez MA, Ocqueteau M, Bertín P, Lira P, Valbuena J. Hairy cell leukemia during pregnancy: report of one case. Rev Med Chil. 2010;138(11):1422-1426. https://doi.org//S0034-98872010001200012
  16. Adeniji BA, Fallas M, Incerpi M, Hamburg S, Katz R, Ogunyemi D. Laparoscopic splenectomy for hairy cell leukemia in pregnancy. Case Rep Med. 2010;2010.pii: 136823. https://doi.org/10.1155/2010/136823
  17. Daver N, Nazha A, Kantarjian H M, Haltom R, Ravandi F. Treatment of Hairy Cell Leukemia During Pregnancy: Are Purine Analogues and Rituximab Viable Therapeutic Options. Clin Lymphoma Myeloma Leuk. 2013;13(1):86-89. https://doi.org/10.1016/j.clml.2012.06.009
  18. Orlowski RZ. Successful pregnancy after cladribine therapy for hairy cell leukemia. Leuk Lymphoma. 2004;45:187-188. https://doi.org/10.1080/1042819031000149458
  19. Alothman A, Sparling TG. Managing hairy-cell leukemia in pregnancy. Ann Intern Med. 1994;120:1048-1049. https://doi.org/10.7326/0003-4819-120-12-199406150-00019
  20. Patsner B., Penney R.W., Walsh C.M. Recurrent hairy cell leukemia during pregnancy: a case report. Am J Obstet Gynecol. 1994;170(5 Pt 1):1380-1381. https://doi.org/10.1016/s0002-9378(13)90471-3
  21. Bhandari A, Rolen K, Shah K. Management of chronic myelogenous leukemia in pregnancy. Anticancer Research. 2015;35:1-12.
  22. Roth MS, Foon KA. Alpha interferon in the treatment of hematologic malignancies. Am J Med. 1986;81(5):871-882. Review. https://doi.org/10.1016/0002-9343(86)90360-8
  23. Zhou L, You JH, Wu W, Li JM, Shen ZX, Wang AH. Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor. Leuk Res. 2013;37(10):1216-1221. https://doi.org/10.1016/j.leukres.2013.07.020
  24. Yazdani BP, Matok I, Garcia BF, Koren G. A systematic review of the fetal safety of interferon alpha. Reprod Toxicol. 2012; 33(3):265-268. https://doi.org/10.1016/j.reprotox.2011.11.003
  25. Al Bahar S, Pandita R, Nath SV. Pregnancy in chronic myeloid leukemia patients treated with alpha interferon. Int J Gynaecol Obstet. 2004;85(3):281-282. https://doi.org/10.1016/j.ijgo.2003.11.01
  26. Mubarak AA, Kakil IR, Awidi A, Al-Homsi U, Fawzi Z, Kelta M, Al-Hassan A. Normal outcome of pregnancy in chronic myeloid leukemia treated with interferon-alpha in 1st trimester: report of 3 cases and review of the literature. Am J Hematol. 2002;69(2):115-118. https://doi.org/10.1002/ajh.9876
  27. Hiratsuka M, Minakami H, Koshizuka S, Sato I. Administration of interferon-alpha during pregnancy: effects on fetus. J Perinat Med. 2000;28(5):372-376. https://doi.org/10.1515/jpm.2000.047
  28. Lau C, Narotsky MG, Lui D, Best D, Setzer RW, Mann PC, Wubah JA, Knudsen TB. Exposure-disease continuum for 2-chloro-2’-deoxyadenosine (2-CdA), a prototype teratogen: induction of lumbar hernia in the rat and species comparison for the teratogenic responses. Teratology. 2002;66:6-18. https://doi.org/10.1002/tera.10039
  29. Schröder C, Azimzadeh AM, Wu G, Price JO, Atkinson JB, Pierson RN. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol. 2003;12:19-28. https://doi.org/10.1016/s0966-3274(03)00059-5
  30. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117:1499-1506. https://doi.org/10.1182/blood-2010-07-295444
  31. Maleka A, Enblad G, Sjörs G, Lindqvist A, Ullenhag GJ. Treatment of metastatic malignant melanoma with vemurafenib during pregnancy. J Clin Oncol. 2013;31(11):e192-e193. https://doi.org/10.1200/JCO.2012.45.2870
  32. Cornet E, Delmer A, Feugier P, Garnache-Ottou F, Ghez D, Leblond V, Levy V, Maloisel F, Re D, Zini JM, Troussard X; French Society of Haematology. Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia. Ann Hematol. 2014; 93(12):1977-1983. https://doi.org/10.1007/s00277-014-2140-y
  33. Robak T, Matutes E, Catovsky D, Zinzani PL, Buske C; ESMO Guidelines Committee. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl.5):v100-v107. https://doi.org/10.1093/annonc/mdv200
  34. Jones G, Parry-Jones N, Wilkins B, Else M, Catovsky D; British Committee for Standards in Haematology. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant. BrJHaematol. 2012;156(2):186-195. https://doi.org/10.1111/j.1365-2141.2011.08931.x
  35. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Российское профессиональное общество онкогематологов, Российская мед. академия последипломного образования МЗ РФ, Национальное гематол. общество. Книга под ред. Поддубной И.В., проф. Савченко В.Г. 2016.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies